Kristin Cadenhead, MD 

Recruitment in progress 
 
This 6-week double-blinded trial examines whether individuals in the early stages of psychosis (EP) respond to 1000 mg of endocannabinoids (CBD) with the aim of improving positive, negative, and cognitive symptoms of psychosis. Researchers are exploring the possibility that CBD might reduce anxiety, and perhaps normalize biological stress response. Symptoms, eating behaviors, metabolic parameters, cannabinoid, and biomarkers of inflammation and cortisol are measured at baseline, 3 weeks and end of study in a population with a diagnosis of first episode psychosis who are stabilized on antipsychotic medication.